Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2009
Revenue:
Royalties and license fees	$ 30,583	$ 34,277	$ 75,464
Product sales	22,965	20,184	19,333
Research and development	14,233	15,437	26,737
Total revenue	67,781	69,898	121,534
Operating costs and expenses:
Product	8,315	9,425	7,508
Customer research and development	18,412	18,147	13,183
Other research and development	12,244	17,916	21,179
Selling, general and administrative	20,545	18,451	17,200
Purchased in-process research and development			3,200
Restructuring charges	2,243	1,306	1,763
Asset impairment charges	28,066	4,896
Goodwill impairment charges	5,650	13,810
Total operating costs and expenses	95,475	83,951	64,033
(Loss) income from operations	(27,694)	(14,053)	57,501
Other income (loss):
Investment income, net	625	1,023	1,839
Impairment loss on cost method investments		(7,943)
Other income, net	401	314	184
Other income (loss), net	1,026	(6,606)	2,023
(Loss) income before income taxes	(26,668)	(20,659)	59,524
Income tax benefit (provision)	8,162	(430)	(21,974)
Net (loss) income	$ (18,506)	$ (21,089)	$ 37,550
Basic net (loss) income per share	$ (1.06)	$ (1.21)	$ 2.15
Diluted net (loss) income per share	$ (1.06)	$ (1.21)	$ 2.15
Weighted average number of shares outstanding:
Basic	17,419	17,372	17,435
Dilutive effect of outstanding stock options and non-vested stock			34
Diluted	17,419	17,372	17,469